Core Insights - A strategic collaboration has been established among InSilico Medicine, Maiwei Biotech, and Haoyuan Pharmaceutical to develop a new library of ADC compounds targeting hundreds of antigens, aiming to accelerate the industrialization of innovative ADC drugs [1][2][3] Group 1: Collaboration Details - The partnership is based on the principles of complementary advantages, resource sharing, collaborative innovation, and mutual benefits [1] - Maiwei Biotech will provide access to hundreds of monoclonal and multi-antibody combinations along with its proprietary ADC technology platform, covering various disease areas such as tumors and autoimmune diseases [1][2] - InSilico Medicine will leverage its Pharma.AI platform to design innovative payload-linkers based on disease mechanisms and target characteristics, showcasing the advantages of AI in drug development [2] Group 2: Industry Impact - This collaboration represents a significant innovation breakthrough in China's biopharmaceutical industry within the ADC drug sector, integrating AI technology with traditional drug development [2] - The partnership aims to create a complete value chain for ADC drug development, enhancing efficiency by shortening the molecular optimization process that traditionally takes years [2] - The collaboration is expected to provide more effective and safer treatment options for global patients by accelerating the development of ADC drugs [3]